Analyst Eric Joseph highlights mid-sized biotech firms for strong pipeline potential and reduced regulatory risks.
Citi analyst Eric Joseph has identified two biotech stocks as top picks for 2026, citing a favorable risk-reward profile in the mid-sized segment. The sector’s appeal stems from high unmet medical needs and potential for first- or best-in-class drug development, despite elevated R&D costs and lengthy approval timelines.
Recent trends support the outlook, including strong launch execution, clinical trial successes, and active mergers and acquisitions. A calmer U.S. regulatory environment and stable drug pricing further bolster confidence in the sector’s growth prospects.
Joseph’s recommendation reflects broader optimism for biotech firms with diversified pipelines and margin expansion opportunities, positioning them for long-term commercial success.